Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Circulating Tumor DNA | 5 | 2024 | 48 | 2.960 |
Why?
|
| Appendiceal Neoplasms | 9 | 2024 | 31 | 2.560 |
Why?
|
| Colorectal Neoplasms | 11 | 2024 | 981 | 2.190 |
Why?
|
| Peritoneal Neoplasms | 11 | 2024 | 184 | 2.130 |
Why?
|
| Hyperthermia, Induced | 8 | 2024 | 73 | 1.620 |
Why?
|
| Colonic Neoplasms | 5 | 2024 | 573 | 1.260 |
Why?
|
| Rectal Neoplasms | 4 | 2024 | 127 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1365 | 0.830 |
Why?
|
| Precision Medicine | 1 | 2024 | 410 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 2566 | 0.670 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1549 | 0.660 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2024 | 76 | 0.560 |
Why?
|
| Adenocarcinoma | 6 | 2024 | 1194 | 0.560 |
Why?
|
| Fluorouracil | 3 | 2024 | 561 | 0.460 |
Why?
|
| Neoplasm Staging | 4 | 2024 | 2018 | 0.380 |
Why?
|
| Radiosurgery | 2 | 2024 | 288 | 0.360 |
Why?
|
| Liver Neoplasms | 3 | 2024 | 758 | 0.330 |
Why?
|
| Humans | 31 | 2024 | 89349 | 0.310 |
Why?
|
| Mutation | 6 | 2024 | 4143 | 0.300 |
Why?
|
| Celecoxib | 2 | 2024 | 31 | 0.290 |
Why?
|
| Combined Modality Therapy | 7 | 2024 | 1719 | 0.280 |
Why?
|
| Retrospective Studies | 11 | 2024 | 9057 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 3 | 2024 | 377 | 0.280 |
Why?
|
| Survival Rate | 7 | 2023 | 1901 | 0.270 |
Why?
|
| Male | 14 | 2024 | 42410 | 0.260 |
Why?
|
| Female | 14 | 2024 | 46200 | 0.250 |
Why?
|
| Middle Aged | 11 | 2024 | 25974 | 0.240 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6811 | 0.240 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2024 | 33 | 0.240 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 64 | 0.230 |
Why?
|
| Adult | 10 | 2024 | 26607 | 0.230 |
Why?
|
| Quinolines | 1 | 2024 | 91 | 0.230 |
Why?
|
| Phenylurea Compounds | 1 | 2024 | 115 | 0.230 |
Why?
|
| Peritoneum | 4 | 2024 | 57 | 0.220 |
Why?
|
| Surgical Oncology | 1 | 2023 | 27 | 0.220 |
Why?
|
| Aged | 7 | 2024 | 19165 | 0.220 |
Why?
|
| Appendix | 1 | 2023 | 31 | 0.210 |
Why?
|
| Vaccines | 1 | 2024 | 83 | 0.210 |
Why?
|
| Cancer Vaccines | 1 | 2024 | 160 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 1 | 2024 | 225 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 192 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 286 | 0.200 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 55 | 0.190 |
Why?
|
| Palliative Care | 1 | 2023 | 264 | 0.190 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 66 | 0.190 |
Why?
|
| Disease-Free Survival | 4 | 2024 | 1214 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 463 | 0.180 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 2362 | 0.180 |
Why?
|
| Mitoxantrone | 1 | 2020 | 68 | 0.180 |
Why?
|
| Etoposide | 1 | 2020 | 206 | 0.170 |
Why?
|
| Cytarabine | 1 | 2020 | 219 | 0.170 |
Why?
|
| Leucovorin | 3 | 2024 | 224 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 969 | 0.160 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 669 | 0.150 |
Why?
|
| Neoplasms | 2 | 2024 | 3041 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 605 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1063 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 1120 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 133 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 793 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2023 | 18 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2023 | 40 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2024 | 487 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2024 | 4289 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2021 | 2415 | 0.090 |
Why?
|
| Recurrence | 2 | 2023 | 1144 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 2869 | 0.070 |
Why?
|
| Quality of Life | 2 | 2024 | 1668 | 0.060 |
Why?
|
| Organoplatinum Compounds | 1 | 2024 | 97 | 0.060 |
Why?
|
| Capecitabine | 1 | 2024 | 98 | 0.060 |
Why?
|
| Standard of Care | 1 | 2024 | 65 | 0.060 |
Why?
|
| Trifluridine | 1 | 2023 | 6 | 0.060 |
Why?
|
| Advance Directives | 1 | 2023 | 64 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2023 | 49 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2023 | 46 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2023 | 94 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 164 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 374 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2024 | 179 | 0.050 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 112 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2024 | 227 | 0.050 |
Why?
|
| Anal Canal | 1 | 2023 | 88 | 0.050 |
Why?
|
| Monoterpenes | 1 | 2022 | 5 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 315 | 0.050 |
Why?
|
| GPI-Linked Proteins | 1 | 2022 | 51 | 0.050 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2021 | 12 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 332 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 12 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 267 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 261 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 203 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 424 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 396 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 309 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2024 | 8241 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 308 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 302 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 682 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 470 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 414 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2021 | 815 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1243 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 950 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 481 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1719 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1184 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 401 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1489 | 0.040 |
Why?
|
| Length of Stay | 1 | 2021 | 736 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 972 | 0.040 |
Why?
|
| Biomarkers | 1 | 2023 | 1767 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 2558 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1652 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1717 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 3783 | 0.030 |
Why?
|
| Illinois | 1 | 2016 | 480 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 860 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 3384 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 2284 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 6312 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 11761 | 0.020 |
Why?
|
| Animals | 1 | 2021 | 27369 | 0.010 |
Why?
|